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Summary 
This report provides estimates of Australia’s health system expenditure on care for those 
with cancer and on the prevention and treatment of cancer. The report presents cancer 
expenditure by age group, sex and type of cancer, and it compares health system 
expenditure on cancer in 2008–09 to 2004–05 and 2000–01 in constant prices (see Glossary). 
Expenditure estimates included in this report are based on health system expenditure that 
can be directly attributed to cancer. Not included in this analysis are expenditure on items 
such as capital goods, including equipment used exclusively for the treatment of individual 
chronic diseases (such as, linear accelerators for cancer) and expenditure on health 
administration other than for cancer screening programs (see Chapter 3 for more detail). 
All references to “total health system expenditure” within this report relate to “total health 
system expenditure on chronic disease” unless otherwise stated. Not all health system 
expenditure can be allocated to specific diseases. There are other limitations to the data, and 
these are explained in Chapter 2. 
Main findings 
In 2008–09: 
• Total health system expenditure in Australia on cancer and other neoplasms (excluding 
national population screening programs) was $4,526 million, which was 7% of total 
health system expenditure on chronic disease ($65,129 million). Total expenditure 
(in 2008–09 prices) on cancer has increased from $2,894 million in 2000–01 and 
$3,640 million in 2004–05.  
• Cancer ranked sixth in terms of Australia’s estimated total health system expenditure on 
chronic diseases. 
• Cancer expenditure for hospital admitted patient services totalled $3,566 million (79%),  
out-of-hospital services totalled $420 million (9%), and prescription pharmaceuticals totalled 
$540 million (12%). 
• Total health system expenditure for cancer was higher for older age groups; increasing 
from $83 million for people aged 15–24 to a maximum of $1,117 million for those aged 
65–74. 
• Colorectal cancer accounted for the highest expenditure, followed by non-melanoma 
skin cancer, prostate cancer, non-Hodgkin lymphoma, leukaemia, and breast cancer. 
• Expenditure on national population screening programs totalled just over $332.2 million, 
comprising $174.5 million for BreastScreen Australia, $125.2 million for cervical 
screening, and $32.5 million for bowel cancer screening. 
• Total health system expenditure on national population screening programs in  
2000–01 was $184.1 million (BreastScreen Australia and the National Cervical Screening 
Program). In 2008–09, this increased to $332.2 million (current prices) partly due to the 
introduction of the National Bowel Cancer Screening Program in 2006.
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1 Introduction 
Cancer has a significant social and economic impact on individuals, families and the 
community in terms of the provision of health care infrastructure, absence from work and 
premature mortality (ABS 2005). It accounts for a major proportion of total health system 
expenditure in Australia. 
Cancer (also called malignant neoplasm) is a diverse group of diseases characterised by the 
uncontrolled proliferation of abnormal cells (Box 1.1). These abnormal cells invade and 
damage the tissues around them, and sooner or later spread to other parts of the body. This 
can cause further damage and eventually death (AIHW & AACR 2012). Other neoplasms 
include benign, in situ and unspecified neoplasms. 
Cancers are distinguished from each other by the location in the body in which the disease 
began (known as the site) and sometimes by the type of cell involved (known as histology). 
The spread of cancerous cells from the primary tumour to another (that is, secondary) site is 
referred to as metastasis (AIHW & AACR 2012). For example, cancer that begins in the lung 
is called lung cancer, regardless of whether or not it has metastasised (spread) to other sites. 
The original site in which a cancerous tumour is formed is referred to as the primary cancer. 
Box 1.1: Reference to cancer 
Unless otherwise stated, reference to cancer within this report includes malignant 
neoplasms and other neoplasms.  
The number of cancer cases diagnosed in Australia is increasing (see Box 1.2). Between 2001 
and 2007, the number of new cancer cases diagnosed increased by 21% from 90,288 to 
109,623. In 2012, it is estimated that the number of new cases increased to more than 120,700, 
excluding basal and squamous cell carcinoma of the skin (AIHW & AACR 2012). The 
increase in the incidence of cancer can be attributed to many things, including improved 
detection, lifestyle factors, and an ageing population (noting that cancer incidence increases 
with age (Figure 1.1). 
In 2007, prostate cancer was the most commonly diagnosed cancer (with 19,572 cases), 
followed by colorectal cancer (14,624 cases) and breast cancer (12,756 cases). 
In general, previous studies have shown increasing survival trends throughout Australia 
(AIHW 2004; AIHW & AACR 2008; English et al. 2007). In 2006–2010, the 5-year relative 
survival was 66%. That is, people diagnosed with cancer had a 66% chance of surviving for 
at least 5 years compared with their counterparts in the general population (AIHW 2012a). 
At the end of 2007, a total of 339,077 people were alive who had been diagnosed with cancer 
in the previous 5 years (AIHW & AACR 2012). 
In 2010, a total of 42,844 Australians died from cancer. Lung cancer was the most common 
cause of death from cancer (8,099 deaths), followed by bowel cancer (3,982 deaths), prostate 
cancer (3,235 deaths), breast cancer (2,864 deaths) and pancreatic cancer (2,434 deaths) 
(AIHW & AACR 2012). 
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Box 1.2: Incidence of cancer in Australia  
Cancer, with the exception of non-melanoma skin cancer, is a notifiable disease in all 
Australian states and territories. The data are collected by cancer registries and include 
clinical and demographic information about people with newly diagnosed cancer. This 
information is obtained from hospitals, pathologists, radiation oncologists, cancer treatment 
centres and nursing homes. 
Incidence data indicate the number of new cancers that have been diagnosed during a 
specific period, usually 12 months. Data on the incidence of cancer refers to the number of 
cases newly diagnosed and not to the number of people newly diagnosed with cancer. 
The incidence of cancer increases with age and differs between males and females (Figure 
1.1). In 2009, the age-standardised incidence rate for people aged 25–54 was slightly higher 
for females than for males. After the age of 55, the incidence rate was higher for males. 
 
Notes 
1. The rates were standardised to the Australian population as at 30 June 2001. 
2. Cancers coded in ICD-10 as C00-C97, D45, D46, D47.1 and D47.3 with the exception of those C44 codes that indicate basal or squamous 
cell carcinoma of the skin. 
3. Data for this figure are in Appendix Table C1.1. 
Source: AIHW ACIM Books 2009.  
Figure 1.1: Incidence rates of all cancers combined by age at diagnosis, Australia, 2007 
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2 Data sources and methodology 
Expenditure 
The predominant source of information for this report is the AIHW Disease Expenditure 
Database. It provides a broad picture of the use of health system resources classified by 
disease group, and it is a reference source for planners and researchers interested in costs 
and use patterns for particular disease groups. These results are useful for comparing 
expenditure for different diseases and for ranking diseases by levels of expenditure. 
The expenditure estimates reported here provide a broad picture of the use of health system 
resources classified by disease. The method for estimating disease expenditure is a  
‘top–down’ approach where total expenditure across the health system is estimated and then 
allocated to the relevant conditions. This method yields consistency and totals that add up to 
known expenditures. It is not as sensitive or accurate for analysis of absolute costs incurred 
by patients for specific diseases, but it does allow the relative cost of expenditure on diseases 
to be more accurately represented (see Appendix A for the classification codes). 
Estimates in the Disease Expenditure Database are derived by combining information from 
the National Hospital Morbidity Database, the National Public Hospitals Establishments 
Database, the Health Expenditure Database, the National Hospital Cost Data Collection, and 
the Bettering the Evaluation and Care of Health (BEACH) survey. The BEACH survey data 
used for this report were aggregated over 3 years: 2007, 2008 and 2009. 
The AIHW is continually seeking to improve the methods used to produce these estimates. 
As a consequence, disease expenditure estimates are subject to revision, and the most 
recently published results might not be comparable with previously published data. 
The Disease Expenditure Database contains estimates of expenditure by disease category, sex 
and age group for admitted patient hospital services, out-of-hospital medical services, and 
prescription pharmaceuticals. 
A data quality statement for the Disease Expenditure Database is in Appendix B. This 
provides information on a range of aspects of the quality of the data being reported by the 
AIHW. It is included to help readers understand the limitations of the data so they can make 
informed judgments about their use of the data. 
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It is not possible to allocate all expenditure on health goods and services by disease. 
Expenditure that could not be allocated by disease includes: 
• capital expenditure  
• non-admitted patient hospital services 
• over-the-counter drugs 
• community health services (except community mental health) 
• other health practitioner services (except optometry) 
• public health programs (except population screening programs) 
• health administration 
• health aids and appliances 
• patient transport (ambulance) 
• research. 
This underestimation can vary between diseases, but the expenditure estimates are 
considered to be a good guide to the relative distribution of expenditure between diseases. 
Readers need to bear in mind that cost-of–illness data provide only estimates of the impact a 
disease has on health system expenditures. The estimates of the cost of treating or preventing 
a disease do not measure loss of productivity, inability to work, and loss of income. 
Estimated expenditure for out-of-hospital medical services and pharmaceuticals requiring a 
prescription are reliant on sample survey data that can vary from year to year. Time-series 
comparisons should be treated with caution. 
Expenditure associated with disease treatment should not be interpreted as simply an 
estimate of the savings that would result from prevention of disease. Conversion of the 
opportunity cost—or the benefits forgone—of resources being devoted to disease treatment 
into expenditure savings involves a number of additional considerations (see, for example 
Mathers & Penm 1998). 
Hospital admitted patients 
The proportions of total expenditure in public acute hospitals that relate to admitted patients 
are estimated using the ‘admitted patient costs proportion’ estimated by each state and 
territory and published in Australian Hospital Statistics 2010–11 (AIHW 2012b). Private 
hospital expenditure data are derived from the Australian Bureau of Statistics Private Health 
Establishments Survey. 
The expenditure method estimates acute hospital admitted patient costs by apportioning the 
total admitted patient expenditure to individual episodes of hospitalisation, with an 
adjustment for the resource intensity of treatment for the specific episode (using the 
Diagnostic Related Groups, or DRGs) and the length of stay (see Box 2.1). Length of stay is 
adjusted to reflect the fact that some costs are proportional to length of stay (for example, 
ward costs and meals) whereas others are independent of length of stay (for example, theatre 
costs). The subdivision of episode costs into these categories is made using the National 
Hospital Costs Data Collection data.  
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The standard DRG method for estimating costs uses state DRG weights, and so assumes that 
the hospital has the same average costliness as the average for the state. DRGs can lack 
sensitivity and specificity with regard to reasons for hospitalisations. 
The Establishments Database contains the actual cost of treating admitted patients at each 
hospital, and these data are used to scale up or down the estimate that comes from using 
whole-of-state DRG weights. 
For subacute and non-acute patients, where there are no DRG weights, the most recent data 
on costs comes from the July to December 1996 subacute and non-acute patient (SNAP) 
study (Eagar et al. 1997). Costs based on day rates have been applied and adjusted to 2000–01 
prices using the implicit price deflator for final government consumption expenditure on 
hospital and nursing home care. 
Principal diagnosis is used to apportion expenditure. Estimates of expenditure on medical 
services for private patients in hospitals are included in admitted patient hospital costs. 
Box 2.1: Interpreting cancer hospitalisations 
The number and rate of hospital admitted cancer-related chemotherapy procedures changes 
over time due to the admission processes of public hospitals in states and territories. These 
hospitals provide same-day chemotherapy for outpatients on a non-admitted basis. This 
means that patients who receive same-day chemotherapy treatment for cancer in those 
hospitals are usually not recorded in the National Hospitals Morbidity Database and will 
contribute to out-of-hospital services expenditure.  
For more information about the National Hospitals Morbidity Database, see the National 
Hospital Morbidity Database data quality statement: 2010–11 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/511338>. 
Out-of-hospital medical services 
Data from the general practitioners’ survey—the BEACH survey—was used to allocate 
private medical services provided by both general practitioners (GPs) and specialists. The 
International Classification of Primary Care Version 2 codes (ICPC2) were mapped to the 
disease costing-groups to enable medical services expenditure to be allocated by disease. 
For out-of-hospital medical services, the BEACH data were aggregated over 3 years (2007, 
2008 and 2009) to estimate the proportion of GP encounters in which cancer was a ‘problem 
managed’. This proportion was then applied to the Medicare Benefits Schedule (MBS) data 
for the reference year. 
Expenditures for ‘Unreferred attendances’, ‘Imaging’ and ‘Pathology’ were allocated to 
disease on the basis of GP encounters, and expenditure for ‘Other medical services’  
(i.e. specialist services) was allocated to diseases on the basis of the referral pattern in 
BEACH. Allocation of GP costs where there were multiple presenting conditions in the GP 
encounter was done on a pro rata basis. For example, expenditure is apportioned equally 
three ways if a patient has three problems managed. Total expenditure was from the health 
expenditure database, which was derived from Medicare Australia data. 
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Pharmaceuticals 
Cancer expenditure estimates for pharmaceuticals provided out-of-hospital are derived 
using the BEACH survey data in conjunction with data from a number of other sources 
including the MBS, Pharmaceutical Benefits Scheme, Repatriation Pharmaceutical Benefits 
Scheme, and script volumes for private and under co-payment drugs. The BEACH data were 
previously collected by the Family Medicine Research Centre of the University of Sydney in 
collaboration with the AIHW. This collaboration concluded in June 2011. 
For cancer management medications, the BEACH survey data were aggregated over 3 years 
to allocate expenditure on prescription drugs to each disease group based on the problems 
managed in the GP encounter that related to the prescribing of a particular drug. 
The Anatomical Therapeutic Chemical Classification System codes were mapped to codes for 
prescription drugs used in the BEACH survey. Time-series comparisons for both  
out-of-hospital medical services and prescription pharmaceuticals should be treated with 
caution because GP prescription and referral patterns could have varied over time. 
Only drugs prescribed specifically for cancer are included in the expenditure in this report. 
Pharmaceuticals dispensed in hospitals are included in the estimates of hospital costs. 
AIHW National Mortality Database 
The AIHW National Mortality Database contains information provided by the Registries of 
Births, Deaths and Marriages, the Australian Bureau of Statistics (ABS) and the National 
Coronial Information System, for deaths from 1964 to 2011. 
Registration of deaths is the responsibility of the state and territory Registrars of Births, 
Deaths and Marriages. These data are collated and coded by the ABS. 
In the AIHW National Mortality Database, both the year of occurrence of the death and the 
year in which the death was registered are provided. For this report, unless otherwise stated, 
mortality data relate to the year of death. 
Statements on data quality relating to the AIHW National Mortality Database are available 
from the ABS website: 
1. Quality declaration summary, Deaths, Australia, 2011, ABS Cat. no 3302.0  
<http://www.abs.gov.au/AUSSTATS/abs@.nsf/Latestproducts/3302.0Quality%20Decl
aration02011?opendocument&tabname=Notes&prodno=3302.0&issue=2011&num=&vie
w=>. 
2. Quality declaration summary, Causes of death, 2011, ABS Cat. no. 3303.0 
<http://www.abs.gov.au/AUSSTATS/abs@.nsf/Latestproducts/3303.0Quality%20Decl
aration02011?opendocument&tabname=Notes&prodno=3303.0&issue=2011&num=&vie
w=>. 
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3 Total health system expenditure on 
cancer and population screening 
programs 
Cancer management 
Health system expenditure on cancer includes expenditure funded by Australian and state 
and territory governments, private health insurers, and individuals and households. 
Expenditure not allocated by disease and therefore not presented in this report includes 
capital expenditure and capital consumption, patient transport, health administration (except 
in the case of population screening programs), health aides and appliances. 
In 2008–09, cancer accounted for 7% ($4,526) of the $65,129 million spent for all chronic 
diseases in Australia (Table 3.1), making cancer the sixth highest in terms of total health 
system expenditure. 
Hospital admitted patient services  
The health-care sector with the highest level of cancer-related expenditure in 2008–09 was 
hospital admitted patient services ($3,566 million), accounting for 79% of total health system 
expenditure for cancer. Hospital admitted patient services also include services provided to  
day-admitted patients. 
Out-of-hospital sector 
The out-of-hospital sector expenditure on cancer, including general practitioner, imaging, 
pathology and other medical services, totalled $420 million, which accounted for 9% of total 
health system expenditure on cancer. 
Prescription pharmaceuticals 
Expenditure on prescription pharmaceuticals obtained outside hospital totalled $540 million, 
accounting for 12% of total health system expenditure on cancer. In-patient and 
day-admitted patient hospital pharmaceuticals are included in hospital expenditure  
(Table 3.1). 
Table 3.1: Cancer and all chronic disease expenditure by area of expenditure, 2008–09 
 Cancer(a)  All chronic diseases 
Area of expenditure $ (million) Per cent  $ (million) Per cent 
Hospital admitted patient services 3,566 78.8  38,675 59.4 
Out-of-hospital services 420 9.3  15,871 24.4 
Prescription pharmaceuticals 540 11.9  10,583 16.2 
Total allocated expenditure(b) 4,526 100.0  65,129 100.0 
(a) Includes cancers coded in the International Statistical Classification of Disease and related health Problems, 10th edition (ICD-10) as  
C00–C97 and D00–D48. 
(b) Total expenditure does not include cancer screening. Components may not sum to the total due to rounding. 
 8 Health system expenditure on cancer and other neoplasms in Australia: 2008-09 
Source: AIHW Disease expenditure database. 
Health system expenditure for cancer is distributed differently to that of all chronic diseases 
(see Table 3.1). For example, expenditure on cancer for hospital admitted patient services 
accounted for 79% of total health system expenditure on cancer. In comparison, just over 
59% of expenditure on all chronic diseases was for hospital admitted patient services. 
Conversely, the proportion of total expenditures allocated to cancers for out-of-hospital 
services (9%) and prescription pharmaceuticals (12%) sectors were much lower than their 
equivalent for all chronic diseases, 24% and 16%. 
Cancer screening programs 
National cancer population screening programs aim to reduce illness and death resulting 
from cancer through an organised approach to screening. Australia has three cancer 
screening programs: 
• BreastScreen Australia 
• National Cervical Screening Program 
• National Bowel Cancer Screening Program. 
BreastScreen Australia 
Australia’s national breast cancer screening program was established as the National 
Program for the Early Detection of Breast Cancer. This program is now known as 
BreastScreen Australia, and is a joint program of the Australian and state and territory 
governments. The program targets asymptomatic women aged 50–69 for free 2-yearly 
screening mammograms to detect cases of breast cancer in women, enabling intervention at 
an early stage (AIHW & AACR 2012). 
National Cervical Screening Program 
In 1991, the Australian Health Ministers’ Advisory Council (AHMAC) accepted 
recommendations made by the Screening Evaluation Steering Committee in the report 
Cervical cancer screening in Australia: options for change (AHMAC 1991) that saw the 
establishment of the Organised Approach to Preventing Cancer of the Cervix, Australia’s 
cervical screening program. Now known as the National Cervical Screening Program, 
Australia’s cervical screening program operates as a joint program of the Australian 
Government and state and territory governments, targeting women aged 18–69 years. 
National Bowel Cancer Screening Program  
The National Bowel Cancer Screening Program was implemented in August 2006 by the 
Australian Government, in partnership with state and territory governments following the 
success of the Bowel Cancer Screening Pilot Program. Data are available only for 2008–09, so 
they cannot be used to present expenditure over time. 
The program currently offers free bowel cancer screening using a faecal occult blood test to 
people turning 50, 55, 60 and 65 years of age. The program is scheduled to be expanded from 
July 2015, with phasing in of biennial screening for those aged 50 to 74. 
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Participation in national population screening programs 
Participation in national cancer screening programs allows for early detection of cancers and 
is associated with improved morbidity and mortality outcomes. 
More than 1.3 million women had a screening mammogram through Breastscreen Australia 
in 2008 and 2009. This was 55% of women in the target age group. In 2009 and 2010, this 
increased to more than 1.7 million Breastscreen Australia mammograms (AIHW & AACR 
2012). 
In the 2-year period 2008–2009, just over 3.6 million women aged 20–69 participated in the 
National Cervical Screening Program. This equated to 58% of eligible women (AIHW 2011). 
In 2009–10, some 3.6 million women aged 20–69 participated in the National Cervical 
Screening Program (Figure 3.1). 
In 2008–09, the National Bowel Cancer Screening Program invited about 780,000 eligible 
Australians to participate and nearly 304,000 people returned a completed faecal occult 
blood test kit for analysis. In 2011–12, 929,433 eligible people were invited into the program. 
A total of 325,276 (35.0%) had participated by 31 December 2012 (AIHW 2013). 
 
Note: Data for this figure are in Appendix Table C3.2. 
Source: National Bowel Cancer Screening Program Register; AIHW analysis of state and territory cervical cytology register data; AIHW analysis of 
BreastScreen Australia data. 
Figure 3.1: National screening program participation numbers, targeted participants, Australia, 
2000–01, 2004–05 and 2008–09 
Health system expenditure on national population screening 
programs 
BreastScreen Australia expenditure increased from $95.9 million in 2000–01, to $174.5 million 
in 2008–09. National Cervical Screening Program expenditure increased from just over 
$88.2 million to $125.2 million in current prices (Figure 3.2). 
BreastScreen Australia Cervical screening Bowel cancer screening
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As the National Bowel Cancer Screening Program was not implemented until 2006, 
expenditure data are limited to 2008–09. In 2008–09, Bowel Cancer Screening Program 
expenditure totalled $32.5 million. 
 
Notes  
1. National screening program data are in current prices. 
2. Data for this figure are in Appendix Table C3.1. 
Source: AIHW disease expenditure database. 
Figure 3.2: Total health system expenditure on screening programs, Australia, 2000–01, 2004–05 and 
2008–09 
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Total expenditure on cancer compared to other 
chronic diseases 
In 2008–09, cancer ranked sixth in terms of estimated health system expenditure on chronic 
diseases. Cancer accounted for 7% of total health system expenditure on all chronic diseases. 
This excludes national population cancer-screening programs. 
Figure 3.3 shows the proportion of health system expenditure by broad disease group in 
2008–09. Cardiovascular disease accounted for the highest proportion of health system 
expenditure in 2008–09, totalling $7,741 million (10.4%). This was followed by: 
• oral diseases, totalling $7,176 million (9.7%) 
• mental disorders, $6,375 million (8.6%) 
• musculoskeletal, $5,671 million (7.6%) 
• injuries, $5,184 million (7.0%). 
 
Notes 
1. Burden of disease categories were used to produce this graph to allow all disease groups to be included. 
2. Percentages do not add up to 100 because not all diseases are included. 
3. Data for this figure are in Appendix Table C3.3. 
Source: AIHW disease expenditure database. 
Figure 3.3: Proportion of health system expenditure on chronic diseases by disease group, 2008–09 
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4 Expenditure on cancer by sex 
In contrast to many other chronic diseases, many cancers are ‘gender related’. That is, they 
either affect women or men due to the origin or localisation of the cancer on the genital 
organs, or the link with ‘secondary sexual characteristics’. These include cervical and ovarian 
cancers in the case of women, and prostate and testicular cancers in the case of men 
(European Commission 2009). 
In 2008–09, the top six cancers in terms of health system expenditure in Australia accounted 
for 42% of total health system expenditure on cancer (Table 4.1). Total estimated expenditure 
on cancer was higher for males, totalling $2,467 million (54.5%), than for females, totalling 
$2,059 million (45.5%). 
For males, the top six cancers in terms of estimated health system expenditure accounted for 
50% of total male health system expenditure on cancer. These were: prostate cancer, totalling 
$347 million (14.0%); colorectal cancer at $248 million (10.0%); non-melanoma skin cancer at 
$219 million (8.9%); leukaemia at $152 million (6.2%); non-Hodgkin lymphoma at 
$149 million (6.0%) and lung cancer at $123 million (5.0%). 
For females, the top six cancers in terms of health system expenditure accounted for 42% of 
total female health system expenditure on cancer. These were: breast cancer, totalling 
$235 million, (11.4%); colorectal cancer at $180 million (8.7%); non-melanoma skin cancer at 
$148 million (7.2%); non-Hodgkin lymphoma at $114 million (5.5%); leukaemia at 
$104 million (5.1%), and lung cancer at $87 million (4.2%). 
Table 4.1: Expenditure by health-care sector, all persons, males and females, 2008–09 
 
Hospital 
admitted 
patients 
($m) 
Out-of-
hospital  
($m)(a) 
Pre-
scription 
pharma-
ceuticals 
($m) 
Total 
expenditure 
($m) 
Proportion 
of all 
cancer 
expenditure 
(%)  
New 
cases  
in 2007 
(No.) 
Deaths in 
2007 
(No.)(b) 
5-year  
pre-
valence 
(No.)(c) 
All persons          
Colorectal 387.90 18.25 21.20 427.35 9.4  14,624 4,182 47,397 
NMSC(d) 224.59 133.07 9.71 367.37 8.1  n.a. 460 n.a. 
Prostate 194.53 30.22 121.85 346.60 7.7  19,572 2,988 72,590 
Non-
Hodgkin 
lymphoma 170.24 6.81 85.80 262.85 5.8  4,111 1,365 14,087 
Leukaemia 243.98 5.08 7.49 256.55 5.7  2,902 1,486 8,084 
Breast 147.24 29.15 60.49 236.88 5.2  12,756 2,747 55,974 
Total (mo.) 1,368.48 222.58 306.54 1,897.60 41.9  54,701 13,228 194,811 
Total (%)(e) 38 53 57 . . . .  50 32 57 
Other cancers 2,197.26 197.90 233.39 2,628.55 58.1  54,922 27,724 149,424 
All cancers 3,565.73 420.48 539.93 4,526.15 100.0  109,623 40,952 349,951 
(Continued) 
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Table 4.1 (continued): Expenditure by health-care sector, all persons, males and females, 2008–09 
 
Hospital 
admitted 
patients 
($m) 
Out-of-
hospital  
($m)(a) 
Pre-
scription 
pharma-
ceuticals 
($m) 
Total 
expenditure 
($m) 
Proportion 
of all 
cancer 
expenditure 
(%)  
New 
cases  
in 2007 
(No.) 
Deaths in 
2007 
(No.)(b) 
5-year  
pre-
valence 
(No.)(c) 
Males          
Prostate 194.53 30.22 121.85 346.60 14.0  19,572 2,988 72,914 
Colorectal 217.98 11.91 17.62 247.50 10.0  7,972 2,275 25,864 
NMSC(d) 135.94 77.46 5.66 219.05 8.9  n.a. 316 n.a. 
Leukaemia 141.92 2.78 7.44 152.14 6.2  1,783 901 4,875 
Non-
Hodgkin 
lymphoma 101.36 4.19 43.32 148.87 6.0  2,238 755 7,743 
Lung 111.54 6.92 4.07 122.53 5.0  6,045 4,806 7,436 
Total (no.) 903.27 133.48 199.96 1,236.69 50.1  38,062 12,041 115,597 
Total (%)(e) 47 64 58 . . . .  61 52 62 
Other cancers 1,012.05 76.25 141.99 1,230.29 49.9  24,671 11,150 72,914 
All cancers 1,915.32 209.74 341.94 2,467.00 100.0  62,733 23,191 192,859 
Females          
Breast 146.33 28.90 59.40 234.63 11.4  12,653 2,722 55,546 
Colorectal 169.93 6.33 3.58 179.85 8.7  6,652 1,907 21,533 
NMSC(d) 88.65 55.61 4.05 148.31 7.2  n.a. 144 n.a. 
Non-
Hodgkin 
lymphoma 68.88 2.61 42.48 113.98 5.5  1,873 610 6,344 
Leukaemia 102.06 2.30 0.05 104.41 5.1  1,119 585 3,209 
Lung 77.02 4.37 5.31 86.70 4.2  3,830 2,938 5,213 
Total (no.) 652.87 100.12 114.87 867.88 42.1  26,411 8,906 90,681 
Total (%)(e) 40 48 58 . . . .  56 50 59 
Other cancers 997.55 110.62 83.11 1,191.27 57.9  20,479 8,855 64,289 
All cancers 1,650.41 210.75 197.99 2,059.14 100  46,890 17,761 157,092 
(a)  Out-of-hospital services includes unreferred attendances, imaging, pathology and other medical services. 
(b)  Deaths registered in 2007 are based on the final version of cause-of-death data. 
(c)  See glossary for definition. 
(d) Non-melanoma skin cancer (NMSC). The two most common types of NMSC are not notifiable diseases. Therefore the incidence and 
prevalence of non-melanoma skin cancer are unknown. 
(e) Expenditure on the six most expensive cancers as per cent of all cancers. 
Notes  
1. Benign myomas, other malignant neoplasms and other benign neoplasms are excluded from the six most expensive cancers. 
2. The mortality data in the AIHW National Mortality Database were provided by the Registries of Births, Deaths and Marriages and the 
National Coronial Information System and coded by the Australian Bureau of Statistics.  
3. Number of deaths in the table refers to the year of occurrence of death. 
Sources: AIHW disease expenditure database; AIHW Australian Cancer Database 2009; analysis of AIHW National Mortality Database. 
There were 109,623 new cases of cancer diagnosed in 2007: 62,733 for males and 46,890 for 
females were diagnosed. The six cancers with the highest health system expenditure 
accounted for 61% of all new cancer cases in males and 56% in females. 
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At the end of 2007, there were 349,951 people in Australia (192,859 males and 157,092 
females) who had been diagnosed with cancer in the previous 5 years and were still alive. 
The six cancers with the highest health system expenditure accounted for 57% of all people 
who had been diagnosed with cancer in the previous 5 years and were still alive. 
There were 40,952 deaths due to cancer in 2007, 23,191 males and 17,761 females. The six 
cancers with the highest health system expenditure accounted for 32% of all deaths from 
cancer in 2007. 
Figure 4.1 shows total health system expenditure for each of the six cancers with the highest 
health system expenditure for males or females by age group. 
 
 
 
 
Note: Data for this figure are in Appendix Table C4.1. NMSC is non-melanoma skin cancer. 
Source: AIHW disease expenditure database. 
Figure 4.1: Health system expenditure on major cancers, by sex, Australia, 2008–09 
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5 Expenditure on cancer by age group  
Total health system expenditure on cancers varies considerably between age groups 
(Figure 5.1). This report focuses on four main age groups, which correspond with four broad 
life stages: children (0–14), adolescents and young adults (15–24), adults (25–64), and older 
adults (65 and over). 
In 2008–09, total health system expenditure on cancer for children aged 0–14 totalled 
$122 million, which was 2.7% of health system expenditure on cancer. Expenditure was 
slightly lower for those aged 15–24, totalling $83 million (1.8%). 
Expenditure increased considerably with age, with the highest expenditure of $1,117 million 
(24.7%) for people aged 65–74. Expenditure then reduced ($941 million, or 20.8%) for those  
aged 75–84, and for those aged 85 and over ($390 million, or 8.6%). 
 
Note: Data for this figure are in Appendix Table C5.1. 
Source: AIHW disease expenditure database. 
Figure 5.1: Health system expenditure by sex and age group, Australia, 2008–09 
For those aged 0–14, 15–24 and 25–34, leukaemia accounted for the highest proportion of 
cancer expenditure. 
For those aged 35–44, brain cancer accounted for the highest proportion of cancer 
expenditure, totalling $32 million.  
For those aged 45–54, breast cancer accounted for the highest proportion of cancer 
expenditure, totalling $53 million.  
For those aged 55–64 to 85 years and above, colorectal cancer accounted for the highest 
proportion of cancer expenditure.  
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Expenditure on cancer for children aged 0–14 
In 2008–09, health system expenditure on cancer for children aged 0–14 was $122 million, 
accounting for 2.7% of total health expenditure on cancer for all ages. The six cancers with 
the highest health system expenditure accounted for 61% of health system expenditure on 
cancer for this age group (Table 5.1 and Figure 5.2). 
Leukaemia accounted for the highest expenditure in this age group, totalling $36.83 million 
(30% of total cancer expenditure). This was followed by brain cancer at $11.76 million (9.6%) 
and multiple myeloma at $11.59 million (9.5%). 
Expenditure on hospital admitted patients totalled $102.76 million, accounting for 84.1% of total 
expenditure in this age group, followed by prescription pharmaceuticals at $12.94 million 
(10.6%) and out-of-hospital services at $6.42 million (5.3%). 
Table 5.1: Expenditure by area of expenditure for cancer, children aged 0–14, 2008–09; number of 
new cancer cases and deaths, 2007 
 
Hospital 
admitted 
patients 
($m) 
Out-of-
hospital  
($m)(a) 
Pre-
scription 
pharma-
ceuticals 
($m) 
Total 
expenditure 
($m) 
Proportion 
of all 
cancer 
expenditure 
(%)  
New 
cases  
in 2007 
(No.) 
Deaths in 
2007 
(No.)(b) 
5-year  
pre-
valence 
(No.)(c) 
All children          
Leukaemia 36.52 0.31 — 36.83 30.2  213 13 876 
Brain 11.76 — — 11.76 9.6  79 38 200 
Multiple 
myeloma(d) — 0.36 11.23 11.59 9.5  — — n.p. 
Bone and 
connective 
tissue  6.16 0.03 0.03 6.21 5.1  47 6 157 
Non-
Hodgkin 
lymphoma 4.42 0.01 — 4.43 3.6  46 n.p. 152 
Kidney  3.47 0.03 — 3.50 2.9  35 n.p. 150 
Total (no.) 62.33 0.74 11.26 74.32 60.9  385 61 1,535 
Total (%)(e) 61 11 87 . . . .  71 66 73 
Other cancers 40.43 5.69 1.68 47.81 39.1  175 31 586 
All cancers 102.76 6.42 12.94 122.13 100.0  595 92 2,122 
(a) Out-of-hospital services includes unreferred attendances, imaging, pathology and other medical services. 
(b) Deaths registered in 2007 are based on the final version of cause-of-death data. 
(c)  See glossary for definition. 
(d) Also includes immunoproliferative cancers. 
(e) Expenditure on the six most expensive cancers as per cent of all cancers. 
Notes  
1. The mortality data in the AIHW National Mortality Database were provided by the Registries of Births, Deaths and Marriages and the 
National Coronial Information System and coded by the Australian Bureau of Statistics. 
2. Number of deaths in the table refers to the year of occurrence of death. 
Sources: AIHW disease expenditure database; AIHW Australian Cancer Database 2009; analysis of AIHW National Mortality Database. 
There were 595 new cases of cancer diagnosed in children aged 0–14 in 2007. Leukaemia  
accounted for the highest incidence in this age group with 213 new cases diagnosed. The six 
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cancers with the highest health system expenditure accounted for 71% of all new cancer 
cases in 2007 in the 0–14 age group. 
At the end of 2007, there were 2,122 children aged 0–14 who had been diagnosed with cancer 
in the previous 5 years and were still alive. The six cancers with the highest health system 
expenditure accounted for 73% of all children who had been diagnosed with cancer in the 
previous 5 years and were still alive. 
There were 92 deaths due to cancer in children aged 0–14 in 2007. Of these, 38 deaths were 
due to brain cancer, the highest number of deaths from any type of cancer in this age group 
in 2007. The six cancers with the highest health system expenditure accounted for 66% of all 
deaths from cancer in this group. 
 
Note: Data for this figure are in Appendix Table C5.2. 
Source: AIHW disease expenditure database. 
Figure 5.2: Health system expenditure all children, aged 0–14, Australia, 2008–09 
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Expenditure on cancer for people aged 15–24 
In 2008–09, health system expenditure on cancer for people aged 15–24 was $83 million, 
accounting for 1.8% of total health expenditure on cancer. The six cancers with the highest 
health system expenditure for people aged 15–24 accounted for 51% of total cancer 
expenditure for this group (Table 5.2, Figure 5.3). 
Leukaemia accounted for the highest expenditure for this age group, totalling $22.59 million 
(27.3%). This was followed by bone and connective tissue, totalling $5.47 million (6.6%), then 
brain cancer at $4.02 million (4.8%). 
Expenditure on hospital admitted patients totalled $69.25 million (83.5%) of total expenditure in 
this age group. This was followed by out-of-hospital services at $12.49 million (15.1%) and 
prescription pharmaceuticals at $1.15 million (1.4%). 
Table 5.2: Expenditure by area of expenditure for cancer, people aged 15–24, 2008–09; number of 
new cancer cases and deaths, 2007  
 
Hospital 
admitted 
patients 
($m) 
Out-of-
hospital  
($m)(a) 
Pre-
scription 
pharma-
ceuticals 
($m) 
Total 
expenditure 
($m) 
Proportion 
of all cancer 
expenditure 
(%)  
New 
cases  
in 2007 
(No.) 
Deaths in 
2007 
(No.)(b) 
5-year  
pre-
valence 
(No.)(c) 
All persons          
Leukaemia 22.43 0.17 — 22.59 27.3  77 36 347 
Bone and 
connective 
tissue 5.20 0.15 0.12 5.47 6.6  62 14 255 
Brain 4.02 — — 4.02 4.8  43 14 152 
Carcinoma in 
situ of cervix 
uteri(d) 3.44 0.17 — 3.61 4.4  n.a. — n.a. 
Hodgkin 
lymphoma 3.21 0.02 — 3.22 3.9  125 n.p. 475 
Non-Hodgkin 
lymphoma 2.98 — — 2.98 3.6  50 n.p. 218 
Total (no.) 41.28 0.51 0.12 41.90 50.5  357 72 1,447 
Total (%)(e) 60 4 10 . . . .  41 53 47 
Other cancers 27.96 11.99 1.03 40.98 49.4  513 63 1,650 
All cancers 69.25 12.49 1.15 82.89 100.0  870 135 3,097 
(Continued) 
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Table 5.2 (continued): Expenditure by area of expenditure for cancer, people aged 15–24, 2008–09; 
number of new cancer cases and deaths, 2007 
 
Hospital 
admitted 
patients 
($m) 
Out-of-
hospital  
($m)(a) 
Pre-
scription 
pharma-
ceuticals 
($m) 
Total 
expenditure 
($m) 
Proportion 
of all cancer 
expenditure 
(%)  
New 
cases  
in 2007 
(No.) 
Deaths in 
2007 
(No.)(b) 
5-year  
pre-
valence 
(No.)(c) 
Males          
Leukaemia 15.41 0.17 — 15.58 37.6  56 24 214 
Bone and 
connective 
tissue 3.00 0.15 0.12 3.27 7.9  42 10 144 
Non-Hodgkin 
lymphoma 2.49 — — 2.49 6.0  32 5 138 
Brain 2.24 — — 2.24 5.4  25 6 85 
Hodgkin's 
lymphoma 1.69 — — 1.69 4.1  55 n.p. 239 
Testicular 1.05 0.07 — 1.12 2.7  103 n.p. 302 
Total (no.) 25.88 0.39 0.12 26.39 63.6  313 49 1,122 
Total (%)(e) 71 8 81 . . . .  67 63 67 
Other cancers 10.36 4.70 0.03 15.09 36.4  153 29 542 
All cancers 36.25 5.08 0.15 41.48 100.0  466 78 1,668 
Females          
Leukaemia 7.02 —  —  7.02 17.0  21 12 133 
Carcinoma in 
situ of cervix 
uteri(d) 3.44 0.17 — 3.61 8.7  n.a. — n.a. 
Bone and 
connective 
tissue 2.20 — — 2.20 5.3  20 4 108 
Brain 1.78 — — 1.78 4.3  18 8 66 
Hodgkin's 
lymphoma 1.52 0.02 — 1.53 3.7  70 n.p. 236 
Thyroid 0.80 0.07 — 0.87 2.1  48 n.p. 162 
Total (no.) 16.76 0.26 — 17.01 41.1  177 25 705 
Total (%)(e) 51 3 0 . . . .  44 44 50 
Other cancers 16.24 7.16 1.00 24.40 58.9  227 32 717 
All cancers 33.00 7.41 1.00 41.41 100.0  404 57 1,429 
(a)  Out-of-hospital services includes, unreferred attendances, imaging, pathology and other medical services. 
(b)  Deaths registered in 2007 are based on the final version of cause-of-death data. 
(c)  See glossary for definition. 
(d)  Carcinoma in situ of the cervix is not a notifiable disease in all states or territories of Australia. Therefore the incidence and prevalence are 
unknown. 
(e)  Expenditure on the six most expensive cancers as per cent of all cancers. 
Notes  
1. The mortality data in the AIHW National Mortality Database were provided by the Registries of Births, Deaths and Marriages and the 
National Coronial Information System and coded by the Australian Bureau of Statistics. 
2. Number of deaths in the table refers to the year of occurrence of death. 
Sources: AIHW disease expenditure database and AIHW; AIHW Australian Cancer Database 2009; analysis of AIHW National Mortality Database. 
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There were 870 new cases of cancer diagnosed in people aged 15–24 in 2007 (466 in males 
and 404 in females). The six cancers with the highest health system expenditure accounted 
for 41% of all new cancer cases in 2007 in this age group. 
At the end of 2007, there were 3,097 people aged 15–24 (1,668 males and 1,429 females) who 
had been diagnosed with cancer in the previous 5 years and were still alive. The six cancers 
with the highest health system expenditure accounted for 47% of all people who had been 
diagnosed with cancer in the previous 5 years in this age group and were still alive. 
There were 135 deaths due to cancer in 15–24-year olds in 2007, of which 78 were male and 
57 were female. The six cancers with the highest health system expenditure accounted for 
53% of all deaths from cancer in 2007. 
In 2008–09, total health system expenditure on cancer for people aged 15–24 totalled $82.89 
million ($41.48 million for males and $41.41 million for females). 
Leukaemia accounted for the highest expenditure for males and females in this age group, 
totalling $15.58 million and $7.02 million respectively (see Figure 5.3). 
 
Note: Data for this figure are in Appendix Table C5.3. 
Source: AIHW disease expenditure database.  
Figure 5.3: Health system expenditure, males and females aged 15– 24, by type of cancer, Australia, 
2008–09 
Expenditure on cancer for people aged 25–64 
In 2008–09, health system expenditure on cancer for people aged 25–64 was $1,873 million, 
accounting for 41.4% of total health expenditure on cancer. The six cancers with the highest 
health system expenditure for people aged 25–64 accounted for 38% of total cancer 
expenditure for this group (Table 5.3). 
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Colorectal cancer accounted for the highest expenditure for this age group, totalling 
$143.58 million (7.7%). This was followed by breast cancer totalling $137.69 million (7.4%) 
and non-melanoma skin cancer at $126.19 million (6.7%). 
Expenditure on hospital admitted patient services totalled $1,542.11 million (82.3% of total 
expenditure in this age group), followed by out-of-hospital services at $208.19 million (11.1%), 
and prescription pharmaceuticals at $122.66 million (6.5%). 
Table 5.3: Expenditure by area of expenditure for cancer, people aged 25–64, 2008–09; number of 
new cancer cases and deaths, 2007 
 
Hospital 
admitted 
patients 
($m) 
Out-of-
hospital  
($m)(a) 
Pre-
scription 
pharma-
ceuticals 
($m) 
Total 
expenditure 
($m) 
Proportion 
of all cancer 
expenditure 
(%)  
New 
cases  
in 2007 
(No.) 
Deaths in 
2007 
(No.)(b) 
5-year  
pre-
valence 
(No.)(c) 
All persons          
Colorectal 119.37 5.49 18.72 143.58 7.7  4,879 1,043 15,157 
Breast 90.24 17.49 29.96 137.69 7.4  8,067 1,161 34,028 
NMSC(d) 68.00 54.18 4.01 126.19 6.7  n.a. 74 861 
Leukaemia 115.53 2.07 4.23 121.84 6.5  1,075 320 3,172 
Prostate 81.44 8.40 13.45 103.29 5.5  7,136 231 21,789 
Non-Hodgkin 
lymphoma 78.46 2.28 0.24 80.99 4.3  1,729 313 6,483 
Total (no.) 533.04 89.92 70.62 713.58 38.1  23,134 3,142 81,490 
Total (%)(e) 36 43 58 . . . .  51 29 53 
Other cancers 989.07 118.27 52.04 1,159.38 61.9  22,670 7,517 73,597 
All cancers 1,542.11 208.19 122.66 1,872.96 100.0  45,804 10,659 155,087 
(Continued) 
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Table 5.3 (continued): Expenditure by area of expenditure for cancer, people aged 25–64, 2008–09; 
number of new cancer cases and deaths, 2007 
 
Hospital 
admitted 
patients 
($m) 
Out-of-
hospital  
($m)(a) 
Pre-
scription 
pharma-
ceuticals 
($m) 
Total 
expenditure 
($m) 
Proportion 
of all cancer 
expenditure 
(%)  
New 
cases  
in 2007 
(No.) 
Deaths in 
2007 
(No.)(b) 
5-year  
pre-
valence 
(No.)(c) 
Males          
Prostate 81.44 8.40 13.45 103.29 11.2  7,136 231 1,789 
Colorectal 69.28 3.11 16.64 89.04 9.7  2,742 603 8,392 
NMSC(d) 41.85 29.86 2.44 74.15 8.0  n.a. 154 487 
Leukaemia 64.63 1.32 4.21 70.15 7.6%  666 194 1,949 
Brain 30.27 0.08 23.37 53.73 5.8  466 341 953 
Non-Hodgkin 
lymphoma 50.21 1.73 0.19 52.13 5.7  964 202 3,655 
Total (no.) 337.68 44.50 60.30 442.49 48.0  12,128 1,626 17,225 
Total (%)(e) 44 52 79 . . . .  51 28 23 
Other cancers 423.63 40.40 15.59 479.62 52.0  11,772 4,213 36,434 
All cancers 761.31 84.9 75.89 922.11 100.0  23,900 5,839 73,659 
Females          
Breast 89.93 17.40 29.91 137.24 14.4  8,030 1,153 33,875 
Colorectal 50.09 2.37 2.08 54.54 5.7  2,137 440 6,765 
NMSC(d) 26.15 24.32 1.57 52.04 5.5  n.a. 94 374 
Leukaemia 50.91 0.75 0.03 51.69 5.4  409 126 1,223 
Lung 26.89 1.64 0.60 29.14 3.1  1,207 824 1,892 
Non-Hodgkin 
lymphoma 28.25 0.56 0.05 28.86 3.0  765 111 2,828 
Total (no.) 272.22 47.05 34.24 353.51 37.2  12,642 2,673 46,957 
Total (%)(e) 35 38 73 . . . .  58 55 58 
Other cancers 508.58 76.25 12.53 597.34 62.8  8,997 2,172 34,471 
All cancers 780.80 123.29 46.77 950.85 100.0  21,904 4,820 81,428 
(a) Out-of-hospital services includes, unreferred attendances, imaging, pathology and other medical services. 
(b) Deaths registered in 2007 are based on the final version of cause-of-death data. 
(c) See glossary for definition. 
(d) Non-melanoma skin cancer (NMSC). The two most common types of NMSC are not notifiable diseases. Therefore the incidence and 
prevalence of NMSC are unknown. 
(e) Expenditure on the six most expensive cancers as per cent of all cancers. 
Notes  
1. The mortality data in the AIHW National Mortality Database were provided by the Registries of Births, Deaths and Marriages and the 
National Coronial Information System and coded by the Australian Bureau of Statistics. 
2. Number of deaths in the table refers to the year of occurrence of death. 
Sources: AIHW disease expenditure database and AIHW; AIHW Australian Cancer Database 2009; analysis of AIHW National Mortality Database. 
There were 45,804 new cases of cancer diagnosed in people aged 25–64 in 2007 (23,900 for 
males and 21,904 for females). The six cancers with the highest health system expenditure 
accounted for 51% of all new cancer cases in 2007 in this age group. 
At the end of 2007, there were 155,087 people aged 25–64 (73,659 males and 81,428 females) 
who had been diagnosed with cancer in the previous 5 years and were still alive. The six 
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cancers with the highest health system expenditure accounted for 53% of all people who had 
been diagnosed with cancer in the previous 5 years in this age group and were still alive. 
There were 10,659 deaths due to cancer among people aged 25–64 in 2007 (5,839 males and 
4,820 females). The six cancers with the highest health system expenditure accounted for 29% 
of all deaths in this age group. 
The 25–64 year age group was the only age group for which total health system expenditure 
on cancer was higher for females than males, totalling $950.85 million and $922.11 million 
respectively. 
Prostate cancer accounted for the highest expenditure for males (totalling $103.29 million), 
and breast cancer in females (totalling $137.24 million) (Figure 5.4). Colorectal cancer 
accounted for the second highest expenditure for both males and females at $89.04 million 
and $54.54 million respectively. 
 
Note: Data for this figure are in Appendix Table C5.4. 
Source: AIHW disease expenditure database. 
Figure 5.4: Health system expenditure, males and females aged 25–64, by type of cancer, Australia, 
2008–09 
Expenditure on cancer for people aged 65 and over 
In 2008–09, health system expenditure on cancer for people aged 65 and over was 
$2,448 million, accounting for 54.1% of total health expenditure on cancer. The six cancers 
with the highest health system expenditure for persons aged 65 and over accounted for 48% 
of total cancer expenditure for this group (Table 5.4). 
Colorectal cancer accounted for the highest expenditure for this age group, totalling 
$283.11 million (11.6%). This was followed by prostate cancer, totalling $241.60 million 
(9.9%), and non-melanoma skin cancer $239.47 million (9.8%). 
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Expenditure on hospital admitted patients totalled $1,851.61 million (75.6% of total expenditure 
in this age group), followed by prescription pharmaceuticals at $403.17 million (16.5%) and  
out-of-hospital services at $193.38 million (7.9%). 
Table 5.4: Expenditure by area of expenditure for cancer, people aged 65 and over, 2008–09; number 
of new cancer cases and deaths, 2007 
 
Hospital 
admitted 
patients 
($m) 
Out-of-
hospital  
($m)(a) 
Pre-
scription 
pharma-
ceuticals 
($m) 
Total 
expenditure 
($m) 
Proportion 
of all cancer 
expenditure 
(%)  
New 
cases  
in 2007 
(No.) 
Deaths in 
2007 
(No.)(b) 
5-year  
pre-
valence 
(No.)(c) 
All persons          
Colorectal 267.87 12.76 2.48 283.11 11.6  9,708 3,131 32,142 
Prostate 112.89 21.82 106.89 241.60 9.9  12,436 2,757 50,798 
NMSC(d) 156.27 77.50 5.70 239.47 9.8  n.a. 386 1,491 
Non-Hodgkin 
lymphoma 84.38 4.51 85.56 174.45 7.1  2,286 1,046 7,234 
Lung 128.59 8.38 7.13 144.10 5.9  7,006 5,704 8,500 
Breast 56.69 11.44 30.38 98.51 4.0  4,680 1,586 21,923 
Total (no.) 806.69 136.41 238.14 1,181.24 48.2  36,596 14,610 122,088 
Total (%)(e) 44 71 59 . . . .  59 49 64 
Other cancers 1,044.92 56.98 165.03 1,266.93 51.8  25,758 15,456 67,557 
All cancers 1,851.61 193.38 403.17 2,448.17 100.0  62,354 30,066 189,645 
(Continued) 
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Table 5.4 (continued): Expenditure by area of expenditure for cancer, people aged 65 and over,  
2008–09; number of new cancer cases and deaths, 2007 
 
Hospital 
admitted 
patients 
($m) 
Out-of-
hospital  
($m)(a) 
Pre-
scription 
pharma-
ceuticals 
($m) 
Total 
expenditure 
($m) 
Proportion 
of all cancer 
expenditure 
(%)  
New 
cases  
in 2007 
(No.) 
Deaths in 
2007 
(No.)(b) 
5-year  
pre-
valence 
(No.)(c) 
Males          
Prostate 112.89 21.82 106.89 241.60 16.9  12,436 2,757 50,798 
Colorectal 148.40 8.80 0.97 158.17 11.0  5,217 1,667 17,433 
NMSC(d) 93.89 46.76 3.22 143.87 10.0  n.a. 261 926 
Non-Hodgkin 
lymphoma 45.65 2.46 43.13 91.24 6.4  1,212 548 3,834 
Lung 78.64 5.65 2.44 86.73 6.1  4,389 3,591 5,189 
Oesophagus 18.98 1.70 32.11 52.80 3.7  555 511 779 
Total (no.) 498.45 87.19 188.76 774.41 54.0  24,101 9,335 78,959 
Total (%)(e) 47 75 75 . . . .  63 54 68 
Other cancers 565.03 29.47 64.40 658.90 46.0  13,940 7,889 37,401 
All cancers 1,063.48 116.66 253.16 1,433.31 100.0  38,041 17,224 116,360 
Females          
Colorectal 119.48 3.96 1.51 124.94 12.3  4,491 1,464 14,709 
Breast 56.09 11.27 29.35 96.71 9.5  4,614 1,569 21,649 
NMSC(d) 62.38 30.74 2.48 95.6 9.4  n.a. 125 565 
Non-Hodgkin 
lymphoma 38.73 2.05 42.43 83.21 8.2  1,074 498 3,400 
Lung 49.95 2.73 4.69 57.37 5.7  2,617 2,113 3,311 
Leukaemia 27.30 1.31 0.03 28.63 2.8  597 440 1,458 
Total (no.) 353.91 52.06 80.49 486.46 47.9  13,581 6,209 45,092 
Total (%)(e) 45 68 54 . . . .  56 48 62 
Other cancers 434.21 24.67 69.52 528.40 52.1  10,732 6,633 28,193 
All cancers 788.13 76.72 150.01 1,014.86 100.0  24,313 12,842 73,285 
(a) Out-of-hospital services includes unreferred attendances, imaging, pathology and other medical services. 
(b) Year of death in table refers to the year of occurrence of death. 
(c) See glossary for definition. 
(d) Non-melanoma skin cancer (NMSC). The two most common types of NMSC are not notifiable diseases. Therefore the incidence and 
prevalence of NMSC are unknown. 
(e) Expenditure on the six most expensive cancers as per cent of all cancers. 
Notes 
1. The mortality data in the AIHW National Mortality Database were provided by the Registries of Births, Deaths and Marriages and the 
National Coronial Information System and coded by the Australian Bureau of Statistics. 
2. Number of deaths in the table refers to the year of occurrence of death. 
Sources: AIHW disease expenditure database and AIHW; AIHW Australian Cancer Database 2009; analysis of AIHW National Mortality Database. 
There were 62,354 new cases of cancer diagnosed among people 65 and over in 2007  
(38,041 for males and 24,313 for females). The six cancers with the highest health system 
expenditure accounted for 59% of all new cancer cases in 2007 in this age group. 
At the end of 2007, there were 189,645 people aged 65 years and over (116,360 males and 
73,285 females) who had been diagnosed with cancer in the previous 5 years and were still 
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alive. The six cancers with the highest health system expenditure accounted for 64% of 
expenditure for of all people who had been diagnosed with cancer in the previous 5 years in 
this age group and were still alive. 
There were 30,066 deaths due to cancer among the 65 and over age group in 2007 (17,224 
males and 12,842 females). The six cancers with the highest health system expenditure for 
people age 65 and over accounted for 49% of all deaths from cancer in 2007. In 2008–09, total 
health system expenditure on cancer in people aged 65 and over totalled $1,433.31 million for 
males and $1,014.86 million for females. 
The highest expenditure on cancer for people in this age group was on prostate cancer for 
males (totalling $241.60 million) and colorectal cancer for females at ($124.94 million) 
(Figure 5.5). 
Colorectal cancer accounted for the second highest expenditure for males, totalling 
$158.17 million. For females, breast cancer accounted for the second highest expenditure at 
$96.71 million. 
 
Note: Data for this figure are in Appendix Table C5.5. 
Source: AIHW disease expenditure database. 
Figure 5.5: Health system expenditure, males and females aged 65 and over, by type of cancer, 
Australia, 2008–09 
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6 Change over time in expenditure on 
cancer 2000–01, 2004–05 and 2008–09 
This chapter describes the change in health system expenditure between 2000–01, 2004–05 
and 2008–09, adjusting for inflation. 
The allocation of health system expenditure statistics over time should be interpreted with 
caution. Variations in hospital admission practices, including cancer-related chemotherapy 
procedures, differ between states and territories. The types of facilities providing services 
also change over time. Hospitals often provide same-day chemotherapy for outpatients on a 
non-admitted basis. 
For example, out-patient activity in South Australia increased between 2006–07 and 2007–08, 
largely due to a change in admission practices for chemotherapy and selected endoscopies. 
In 2006–07, these were treated as same-day admissions, and from 2007–08 onwards, they 
were treated as outpatient occasions of service (AIHW 2012b).  
From 2000–01 to 2008–09, total health system expenditure on cancer increased by 56% from 
$2,894 million to $4,526 million (constant prices). This compares to a total increase of 60% for 
all chronic diseases—from $40,699 million in 2000–01 to $65,129 million in 2008–09. Over the 
same period, total health system expenditure (including chronic disease and other 
expenditure) increased by 52% from $74,679 million in 2000–01 to $113,661 million in 2008–
09. 
Expenditure for hospital admitted patient services was highest in all three years compared with 
out-of-hospital services and prescription pharmaceuticals, increasing from $2,232 million in  
2000–01, then $2,753 million in 2004–05, and ending at $3,566 million in 2008–09 (Figure 6.1). 
Prescription pharmaceuticals also had a steady increase in expenditure from $169 million in 
2000–01, then $239 million in 2004–05, and $540 million in 2008–09. 
Expenditure for out-of-hospital services increased between 2000–01 ($493 million) and  
2004–05 ($648 million) but then reduced considerably in 2008–09 ($420 million). 
Expenditure estimates are, in part, based on survey data, so caution is required when 
interpreting differences and changes over time. 
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Note: Data for this figure are in Appendix Table C6.1. 
Source: AIHW disease expenditure database. 
Figure 6.1: Total health system expenditure on cancer by health-sector, Australia, 2000–01, 2004–05 
and 2008–09 
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7  Discussion 
With 1 in 2 Australians developing cancer, and 1 in 5 dying from it before the age of 85, 
cancer has a major impact on individuals, their families and the health-care system (AIHW & 
AACR 2012). 
Cancer prevalence is trending upwards, both in Australia and globally, with an estimated 
12.7 million cancer cases around the world in 2008. This number is expected to increase to 
21 million by 2030 (WCRF International 2013). This is due to a range of factors, including: 
• increasing population 
• increased life expectancy 
• improved cancer management and treatment (leading to improved survival) 
• ageing population. 
In Australia, total health system expenditure on cancer in 2008–09 (excluding national 
population screening programs) totalled $4,526 million. This has resulted in cancer moving 
from the ninth most expensive chronic disease in 2000–01 to the sixth in 2008–09, overtaking 
respiratory and digestive system diseases. 
Health system expenditure on hospital admitted patient services accounted for the highest 
proportion of expenditure on cancer at 77% ($2,232 million) in 2000–01, 76% ($2,753 million) 
in 2004–05 and 79% ($3,566 million) in 2008–09. 
The health sector that saw the greatest proportional increase in expenditure during this 
period was prescription pharmaceuticals, which increased from 6% of health system 
expenditure ($169 million) in 2000–01, to 7% ($239 million) in 2004–05, and 12% 
($540 million) in 2008–09. New pharmaceuticals that became available, including 
chemotherapy drugs, could have contributed to changes in expenditure on cancer over time. 
Out-of-hospital medical expenses accounted for 17% ($493 million) of health system expenditure 
in 2000–01, increasing slightly to 18% ($648 million) in 2004–05, but then decreasing 
considerably in 2008–09 to 9% ($420 million).  
Expenditure for out-of-hospital services and prescription pharmaceuticals are inextricably linked 
because patients are prescribed medicines directly by their general practitioner or specialist 
physician. Expenditure for medicines prescribed for admitted patents are included in hospital 
admitted patient expenditure.  
Expenditure estimates are largely based on survey data, so caution is required when 
interpreting outcomes. Estimates are believed to underestimate the true level of health 
system expenditure in Australia. The limitations of the data and the methods used are 
important and have been explained in detail in Chapter 2. 
The three national population screening programs are designed to reduce illness and death 
through early detection of cancer and pre-cancerous abnormalities with effective follow-up 
treatment. The programs are BreastScreen Australia, the National Cervical Screening 
Program, and the National Bowel Cancer Screening Program. 
Expenditure on national population screening programs totalled $332 million in 2008–09, 
accounting for around 6.8% of total health system expenditure on cancer. 
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Breast cancer screening accounted for the highest proportion of this expenditure, totalling 
$175 million, followed by cervical screening at $125 million, and bowel cancer screening at 
$33 million. 
The bowel cancer screening program currently offers free screening using a faecal occult 
blood test to people turning 50, 55, 60 and 65 years of age. The program is scheduled to be 
expanded from July 2015, with phasing in of biennial screening for those aged 50 to 74. 
Expenditure for this program is expected to increase as a result of the increase in 
participation. 
Health system expenditures for cancer, as a proportion of total health system expenditure for 
chronic diseases, has remained at 7% from 2000–01 ($2,894 million) to 2008–09 
($4,526 million) (population screening programs excluded). 
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Appendix A Cancer codes 
Cancer site/type ICD-10 codes 
Lip, oral cavity and pharynx 
Lip C00 
Tongue C01–C02 
Mouth C03–C06 
Salivary glands C07–C08 
Oropharynx C09–C10 
Nasopharynx C11 
Hypopharynx C12–C13 
Other sites in pharynx, etc. C14 
Digestive organs 
Oesophagus  C15 
Stomach  C16 
Small intestine  C17 
Bowel C18–C20 
Anus C21 
Liver C22 
Gallbladder & bile ducts  C23–C24 
Pancreas C25 
Other digestive organs C26 
Respiratory system and intrathoracic organs 
Nose, sinuses, etc. C30–C31 
Larynx C32 
Lung C33–C34 
Other thoracic and respiratory organs C37–C39 
Bone C40–C41 
Skin 
Melanoma of the skin C43 
Non-melanoma of the skin C44(a) 
Mesothelioma and soft tissue 
Mesothelioma C45 
Kaposi sarcoma C46 
Peritoneum C48 
Other soft tissue C47, C49 
Breast C50 
 (continued) 
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Cancer site/type ICD-10 codes 
Female genital organs 
Vulva C51 
Vagina C52 
Cervix C53 
Uterus C54–C55 
Ovary C56 
Other female genital organs and placenta C57–C58 
Male genital organs  
Penis C60 
Prostate C61 
Testis C62 
Other male genital organs C63 
Urinary tract  
Kidney C64 
Bladder C67 
Other urinary organs C65–C66, C68 
Eye, brain and other parts of the central nervous system  
Eye C69 
Brain  C71 
Other central nervous system C70, C72 
Thyroid and other endocrine glands  
Thyroid C73 
Other endocrine glands C74–C75 
Blood and lymphatic system  
Hodgkin lymphoma C81 
Non-Hodgkin lymphoma C82–C85 
Immunoproliferative cancers C88 
Myeloma C90 
Acute lymphoblastic leukaemia C91.0 
Chronic lymphocytic leukaemia  C91.1 
Other and unspecified lymphoid leukaemia C91.2–C91.9 
Total lymphoid cancers C81–C85, C88, C90, C91 
Chronic myelogenous leukaemia C92.1 
Other myeloproliferative cancers C94.1, C94.3, C96.2, D45, D47.1, D47.3 
Myelodysplastic syndrome D46 
Acute myeloid leukaemia C92.0, C92.3–C92.5, C93.0, C94.0, C94.2, C94.4, C94.5 
 (continued) 
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Cancer site/type ICD-10 codes 
Unspecified myeloid leukaemia C92.2, C92.7, C92.9, C93.1–C93.9, C94.7 
Total myeloid cancers C92–C94, C96.2, D45, D46, D47.1, D47.3 
Other cancers of the blood and lymphatic system C95, C96.0, C96.1, C96.3–C96.9 
Other   
Other and ill-defined sites C76 
Unknown primary site C80(b) 
Multiple primary C97(c) 
All cancers C00–C96(a), D45, D46, D47.1, D47.3 
(a) For incidence data, those C44 codes that indicate basal or squamous cell carcinoma of the skin are not included. 
(b) For mortality data prior to 2008, the applicable codes are C77–C80. 
(c) Of relevance for mortality data only. 
Source: AIHW Australian Cancer Database 2009. 
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Appendix B Data quality statement 
Disease expenditure database 2008–09 
Summary of key data quality issues 
• The Disease Expenditure Database contains estimates of expenditure by disease 
category, age group and sex for each of the following areas of expenditure: admitted 
patient hospital services, out-of-hospital medical services, prescription pharmaceuticals, 
optometrical and dental services, community mental health services, and public health 
cancer screening. 
• Estimates are derived from combining information from the National Hospital 
Morbidity Database (NHMD), the National Public Hospitals Establishments Database 
(NPHED), the Health expenditure database, the National Hospital Cost Data Collection 
(NHCDC) and the Bettering the Evaluation and Care of Health (BEACH) survey. 
• The database contains a conservative estimate of total expenditure and equates to 
around 70% of total recurrent health expenditure. 
Description 
The Disease Expenditure Database contains estimates of expenditure by disease category, 
age group and sex for admitted patient hospital services, out-of-hospital medical services, 
prescription pharmaceuticals, optometrical and dental services, community mental health 
services and public health cancer screening. Definitions for admitted patient hospital 
services, out of-hospital medical services and prescription pharmaceuticals are as follows: 
Admitted patient hospital costs refer to the cost of services for admitted patients in both 
public and private acute hospitals and psychiatric hospitals, as well as expenditure on 
medical services provided to private admitted patients in hospitals. 
Out-of-hospital medical expenses refer to the cost for services provided by, or on behalf of, 
registered medical practitioners that are funded by the Medicare Benefits Schedule (MBS), 
Department of Veterans’ Affairs, compulsory motor vehicle third-party insurance, workers 
compensation insurance, private health insurance funds, Australian Government premium 
rebates allocated to medical services, MBS co-payments and other out-of-pocket payments. 
They also include non-MBS medical services, such as the provision of vaccines for overseas 
travel, as well as some expenditure by the Australian Government under funding 
arrangements that are alternatives to the fees for service. They exclude medical services 
provided to public admitted patients in public hospitals and medical services provided to 
public patients at outpatient clinics in public hospitals. Also excluded are the costs for 
medical services provided to private admitted patients in hospitals, which are counted as 
part of admitted patient costs. 
Prescription pharmaceuticals refer to the cost of pharmaceuticals that are listed in the 
schedule of the pharmaceuticals under the Pharmaceutical Benefits Scheme (PBS) and the 
Repatriation Pharmaceutical Benefits Scheme (RPBS), for which pharmaceutical benefits 
have been paid or are payable. Also included are the costs for under copayment 
prescriptions and private prescriptions. Under copayment prescriptions are those 
pharmaceuticals listed in the PBS or RPBS, the total costs of which are equal to or less than 
the statutory patient contribution for the class of patient concerned, while private 
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prescriptions are those pharmaceuticals dispensed through private prescriptions that do not 
fulfil the criteria for payment or benefit under the PBS or RPBS. 
Estimates are derived from combining information from the National Hospital Morbidity 
Database (NHMD), the National Public Hospitals Establishments Database (NPHED), the 
National Hospital Cost Data Collection (NHCDC) and the Health expenditure database. 
Proportions derived from the Bettering the Evaluation and Care of Health (BEACH) survey 
relating to 2007 to 2009 are also used in compiling the estimates for out-of-hospital medical 
services and prescription pharmaceuticals. The BEACH data were collected by the Family 
Medicine Research Centre of the University of Sydney in collaboration with the Australian 
Institute of Health and Welfare. 
It is not possible to allocate all expenditure on health goods and services by disease. 
Expenditure that was not able to be allocated by disease includes: capital expenditure, 
non-admitted patient hospital services, over-the-counter drugs, other health practitioner 
services (except optometry), community health services expenditure (except community 
mental health), expenditure on public health programs (except cancer screening programs), 
health administration, health aids and appliances, and patient transport (ambulance). 
Institutional environment 
The Australian Institute of Health and Welfare (AIHW) is a major national agency set up by 
the Australian Government under the Australian Institute of Health and Welfare Act 1987 to 
provide reliable, regular and relevant information and statistics on Australia’s health and 
welfare. It is an independent statutory authority established in 1987, governed by a 
management board, and accountable to the Australian Parliament through the Health 
portfolio. 
The AIHW aims to improve the health and wellbeing of Australians through better health 
and welfare information and statistics. It collects and reports information on a wide range of 
topics and issues, ranging from health and welfare expenditure, hospitals, disease and 
injury, and mental health, to ageing, homelessness, disability and child protection. 
The Institute also plays a role in developing and maintaining national metadata standards. 
This work contributes to improving the quality and consistency of national health and 
welfare statistics. The Institute works closely with governments and non-government 
organisations to achieve greater adherence to these standards in administrative data 
collections to promote national consistency and comparability of data and reporting. 
One of the AIHW’s main functions is to work with the states and territories to improve the 
quality of administrative data and, where possible, to compile national data sets based on 
data from each jurisdiction, to analyse these datasets and disseminate information and 
statistics. 
The Australian Institute of Health and Welfare Act 1987, in conjunction with compliance to the 
Privacy Act 1988 (Cwlth), ensures that the data collections managed by the AIHW are kept 
securely and under the strictest conditions with respect to privacy and confidentiality. 
For further information, see the AIHW website <http://www.aihw.gov.au/>. 
The BEACH survey data 2007–08 and 2008–09 were collected by the Family Medicine 
Research Centre of the University of Sydney in collaboration with the Australian Institute of 
Health and Welfare. Data for the Disease Expenditure Database were derived from data 
from the NHMD, NPHED and Health Expenditure Database as well as survey based data. 
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Timeliness 
The reference period for this data set is 2008–09. The Disease Expenditure Database can only 
be updated once the NHMD, NPHED, NHCDC and Health Expenditure Databases have all 
been updated for the relevant financial year, which is currently a minimum of 15 months 
after the end of the financial year. 
The AIHW first published 2008–09 data from the Disease Expenditure Database in Australia’s 
health 2012 in June 2012. 
Accessibility 
The AIHW provides a variety of products that draw upon the Disease Expenditure Database 
2008–09. Published products currently available on the AIHW website include: 
• Australia’s health 2012 
• Dementia in Australia 
• Incontinence in Australia: prevalence, experience and cost. 
Users can request data not available online or in reports via the Expenditure and Economics 
Unit on (02) 6244 1119 or via email to <expenditure@aihw.gov.au>. Requests that take longer 
than half an hour to compile are charged for on a cost-recovery basis. 
Interpretability 
Supporting information on the quality and use of the Disease Expenditure Database are 
published in Health system expenditure on disease and injury in Australia, 2004–05 (technical 
notes), available in hard copy or on the AIHW website. 
Most important to note is that the Disease Expenditure Database estimates: 
• are a conservative estimate based on around 70% of total recurrent health expenditure 
• are only one measure of the size of the disease burden on the community (that is, the 
‘size of the problem’) 
• are not the same as loss of health due to disease 
• should not be regarded as how much would be saved if a specific disease or all diseases 
were prevented 
• are not an estimate of the total economic impact of diseases in the Australian 
community. This is because the estimates do not include costs that are not accrued by the 
health system, such as travel costs of patients, costs associated with the social and 
economic burden on carers and family, and owing to lost quality and quantity of life. 
Relevance 
Disease expenditure estimates provide a broad picture of the use of health system resources 
classified by disease group, as well as a reference source for planners and researchers 
interested in costs and use patterns for particular disease groups. 
The Disease Expenditure Database contains a conservative estimate based on around 70% of 
total recurrent health expenditure. 
It is not possible to allocate all expenditure on health goods and services by disease. 
Expenditure that was not able to be allocated by disease includes: capital expenditure, 
non-admitted patient hospital services, over-the-counter drugs, other health practitioner 
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services (except optometry), community health services expenditure (except community 
mental health), expenditure on public health programs (except cancer screening programs), 
health administration, health aids and appliances, and patient transport (ambulance). 
Readers need to bear in mind that cost-of-illness data only provide estimates of the impact of 
a disease on health system expenditures. The estimates of the cost of treating and/or 
preventing a disease cannot be used to indicate the loss of health due to that disease. 
Care should be taken not to interpret expenditure associated with disease treatment as 
simply an estimate of the savings that would result from prevention of disease. Conversion 
of the opportunity cost—or the benefits forgone—of resources being devoted to disease 
treatment into expenditure savings involves a number of additional considerations. See, for 
example, AIHW: Mathers & Penm 1998. 
Accuracy 
Apart from hospital admitted patient services data, the method for estimating disease 
expenditure is generally a ‘top–down’ approach, where total expenditure across the health 
system is estimated and then allocated to the relevant conditions. Although this method 
yields consistency, good coverage, and totals that add up to known expenditures, it is not as 
sensitive or accurate for any specific disease as a detailed ‘bottom–up’ analysis of actual costs 
incurred by patients with that disease. In most cases, a more granular analysis is not possible 
due to a lack of available data. 
Both out-of-hospital medical services and prescription pharmaceuticals expenditure 
estimates draw upon proportions derived from BEACH surveys relating to 2007 to 2009. In 
each BEACH survey, the vocationally registered GPs and all general practice registrars who 
claimed a minimum of 375 general practice A1 Medicare items in the most recently available 
3 months make up the population from which a sample is drawn (Britt et al. 2009). GPs are 
randomly selected from this population and approached for participation in the survey. Each 
BEACH survey includes a sample of 1,000 recognised practising GPs across the country 
(about a 6% of all recognised practising GPs) completing details for 100 consecutive GP 
encounters. Each BEACH survey contains details of about 100,000 encounters between GPs 
and patients (about a 0.1% sample of all general practice encounters) (Britt et al. 2009). For 
further information regarding data collection methods in BEACH surveys, refer to the 
General practice activity in Australia 2008–09 report (Britt et al. 2009). In light of these sampling 
methods used, time series comparisons of expenditure estimates for out-of-hospital medical 
services and prescription pharmaceuticals need to be treated with caution. Refer to the data 
quality statements for the NHMD, NPHED and the Health Expenditure Database for further 
information on the accuracy of the data within these databases. 
Coherence 
To ensure consistency between the Disease Expenditure Database and associated burden of 
disease projects, the disease groups used in the 2008–09 disease expenditure estimates were 
based on the 176 diseases that were published in the Australian burden of disease studies 
(AIHW: Mathers et al. 1999; Begg et al. 2007). Extra categories were added to provide a more 
comprehensive list of diseases and the two categories of ‘Symptoms, signs and ill-defined 
conditions’ and ‘Other contact with health services’ were included to cover some health 
service expenditures that cannot be allocated by disease. 
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The methodologies used to estimate expenditures for admitted patient hospital services have 
remained unchanged between 2004–05 and 2008–09. Hence, time series comparisons for 
admitted patient hospital services are possible. 
While the methodologies used to estimate expenditures for out-of-hospital medical services 
and prescription pharmaceuticals have also remained unchanged between 2004–05 and 
2008–09, the use of the BEACH survey-based data in the methodologies has meant that time 
series comparisons for these areas of expenditure should be made with caution. 
Comparisons over time for optometrical and dental services, community mental health 
services and public health cancer screening can be made with more confidence. 
Implementation date 
6 February 2012 
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Appendix C Detailed statistical tables 
Table C1.1: Incidence rates of all cancers  
combined by age at diagnosis, Australia, 2007 
Age Group Males  Females Persons 
0–4 23.72 19.27 21.55 
5–9 10.87 8.46 9.70 
10–14 13.55 13.66 13.60 
15–19 22.44 21.66 22.06 
20–24 39.36 37.76 38.59 
25–29 58.36 66.00 62.12 
30–34 81.47 114.26 97.86 
35–39 114.48 179.04 147.00 
40–44 174.53 281.11 228.20 
45–49 307.84 420.58 364.77 
50–54 566.58 572.27 569.45 
55–59 993.37 745.40 868.26 
60–64 1,554.26 985.27 1,269.43 
65–69 2,239.19 1,247.54 1,738.49 
70–74 2,708.10 1,469.90 2,067.01 
75–79 3,216.99 1,724.47 2,416.17 
80–84 3,581.53 1,989.62 2,665.86 
85+ 3,798.00 2,075.96 2,661.25 
Notes 
1. Rates are per 100,000 population and are age-standardised to  
the Australian population as at 30 June 2001. 
2. Cancers coded in ICD-10 as Coo-C97, D45, D46, D47.1 and  
D47.3 with the exception of those C44 codes which indicate basal 
or squamous cell carcinoma of the skin. 
Source: AIHW ACIM Books 2009. 
Table C3.1: National screening program participation  
numbers, Australia, 2000–01, 2004–05 and 2008–09 
 2000–01 2004–05 2008–09 
Breast cancer screening(a) 1,063,479 1,188,720 1,319,771 
Cervical screening(b) 3,331,408 3,268,984 3,638,941 
Bowel cancer screening(c) 0 0 303,951 
Total 4,394,887 4,457,704 5,232,835 
(a) BreastScreen Australia. 
(b) National Cervical Screening Program. 
(c) National Bowel Cancer Screening Program. 
Source: National Bowel Cancer Screening Program Register; AIHW analysis of  
state and territory cervical cytology register data; AIHW analysis of BreastScreen  
Australia data. 
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Table C3.2: Total health system expenditure on 
screening programs, Australia, 2000–01, 2004–05  
and 2008–09, ($ million)  
 2000–01 2004–05 2008–09 
Breast cancer screening(a) 95.9 118.5 174.5 
Cervical screening(b) 88.2 103.6 125.2 
Bowel cancer screening(c) 0.0 0.0 32.5 
Total 184.1 222.1 332.2 
(a) BreastScreen Australia. 
(b) National Cervical Screening Program. 
(c) National Bowel Cancer Screening Program. 
Source: AIHW disease expenditure database. 
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Table C3.3: Health system expenditure on chronic disease by disease group and area of 
expenditure, 2008-09 ($ million)  
(a) Public and private acute hospitals and psychiatric hospitals. Includes a preliminary estimate of private medical services provided in hospital. 
(b) Out-of-hospital services includes unreferred attendances, imaging, pathology and other medical services. 
(c) All pharmaceuticals for which a prescription is required, including private prescriptions and under co-payment prescriptions, and includes 
over-the-counter medicines such as vitamins and minerals, first aid and would care products, analgesics, feminine hygiene products, cold 
sore preparations, and a number of complimentary health products that are sold in both pharmacy and other retail outlets.  
(d) Includes aged care homes, dental and other professional services, community and public health, and research. Cancer screening is also 
included. 
Source: AIHW disease expenditure database. 
Chronic disease 
Hospital 
admitted 
patients 
($m)(a) 
Out-of-
hospital 
($m)(b)  
Prescription 
pharmaceuticals 
($m)(c) 
Other 
services 
($m)(d)  
Total 
expenditure  
by disease  
($m) 
Proportion of 
total allocated 
expenditure  
(%) 
Cardiovascular 4,518 1,537 1,685 — 7,741 10.4 
Oral health 265 97 24 6,790 7,176 9.7 
Mental disorders 2,695 915 1,057 1,708 6,375 8.6 
Musculoskeletal 3,091 1,661 919 — 5,671 7.6 
Injuries 4,115 923 146 — 5,184 7.0 
Cancer and other 
neoplasms 3,566 420 540 336 4,862 6.5 
Respiratory 2,401 1,343 845 — 4,588 6.2 
Digestive system 2,826 550 701 — 4,076 5.5 
Genitourinary 2,257 918 279 — 3,453 4.7 
Nervous system 
disorders 1,502 841 762 282 3,387 4.6 
Endocrine, nutritional 
and metabolic 814 615 1,204 — 2,634 3.5 
Maternal conditions 2,450 53 10 — 2,514 3.4 
Infectious and parasitic  845 556 254 — 1,654 2.2 
Skin diseases 667 570 360 — 1,597 2.2 
Diabetes mellitus 649 367 505 — 1,521 2.0 
Neonatal causes 766 3 0 — 770 1.0 
Congenital anomalies 378 30 4 — 411 0.6 
Proportion of total (%) 52.1 21.4 14.3 12.3 100.0  
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Table C4.1: Health system expenditure on major cancers, by sex and  
age group, Australia, 2008–09 ($million) 
 Age group (years) 
Sex 0–14 15–24 25–64 65+ 
 Colorectal 
Males 15,321 281,532 89,039,170 158,167,180 
Females 32,660 328,773 54,540,649 124,943,932 
 Leukaemia 
Males 19,753,887 15,578,052 70,154,184 46,650,724 
Females 17,078,354 7,015,520 51,686,088 28,632,156 
 Lung cancer 
Males 1,547 43,584 35,755,786 86,733,002 
Females 131,461 61,018 29,138,632 57,366,118 
 Non-Hodgkin's lymphoma 
Males 3,007,665 2,492,700 52,130,027 91,242,015 
Females 1,420,142 489,867 28,860,107 83,206,243 
 Non-melanoma skin cancer 
Males 79,851 959,241 74,146,737 143,868,517 
Females 32,038 641,298 52,041,906 95,597,071 
 Breast cancer 
Males — — 446,492 1,802,204 
Females 359,092 319,042 137,243,274 96,709,667 
 Prostate cancer 
Males 1,517,549 187,731 103,290,607 241,604,574 
Females — — — — 
Source: AIHW disease expenditure database. 
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Table C5.1: Health system expenditure by sex  
and age group, Australia, 2008–09 ($million) 
Age group  
(years) Males Females 
 
Persons 
0–14 70,099,404 $52,027,698 122,127,102 
15–24 41,480,864 41,407,453 82,888,317 
25–34 49,947,624 74,707,072 124,654,696 
35–44 129,970,510 175,552,716 305,523,227 
45–54 236,363,594 318,569,675 554,933,270 
55–64 505,823,777 382,024,605 887,848,382 
65–74 647,009,031 470,049,032 1,117,058,063 
75–84 563,673,209 377,317,724 940,990,933 
85+ 222,627,290 167,490,448 390,117,738 
 Source: AIHW disease expenditure database. 
 
Table C5.2: Health system expenditure all children  
aged 0–14, by type of cancer Australia, 2008–09  
Cancer type Total expenditure ($m)   
Leukaemia 36,832,242 
Brain 11,761,383 
Multiple myeloma 11,587,969 
Bone and connective tissue  6,211,433 
Non-Hodgkin's  4,427,806 
Kidney  3,500,229 
Liver  1,648,693 
Prostate  1,517,549 
Source: AIHW disease expenditure database. 
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Table C5.3 Health system expenditure people  
aged 15 to 24 years, by type of cancer, Australia,  
2008–09 
Cancer type Total expenditure ($m) 
Leukaemia $22,593,572 
Bone and connective tissue  5,472,428 
Brain  4,024,168 
Carcinoma in situ of cervix uteri 3,606,425.99 
Hodgkin's  3,224,723 
Non-Hodgkin's  2,982,567 
Testicular 1,118,617 
Thyroid 1,046,166 
Source: AIHW disease expenditure database. 
 
Table C5.4 Health system expenditure people aged  
25 to 64 years, by type of cancer, Australia, 2008–09 
Cancer type Total expenditure ($m) 
Colorectal  143,579,819 
Breast  137,689,766 
Non-melanoma skin cancer 126,188,643 
Leukaemia 121,840,272 
Prostate  103,290,607 
Non-Hodgkin's  80,990,135 
Brain 74,306,918 
Lung 64,894,418 
Source: AIHW disease expenditure database. 
 
Table C5.5 Health system expenditure people aged 
 65 years and over, by type of cancer, Australia, 2008–09  
Cancer type Total expenditure ($m) 
Colorectal $283,111,112 
Prostate $241,604,574 
Non-melanoma skin cancer $239,465,588 
Non-Hodgkin's $174,448,258 
Lung $144,099,120 
Breast $98,511,871 
Leukaemia $75,282,880 
Oesophagus $63,349,108 
Source: AIHW disease expenditure database. 
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Table C6.1: Total health system expenditure on cancer by area of expenditure,  
Australia, 2000–01, 2004–05 and 2008–09 ($ million)  
 
Hospital admitted 
patient services    
Out-of-hospital 
medical expenses  
Prescription 
pharmaceuticals  Total expenditure  
2000–01 2,232 493 169 2,894 
2004–05 2,753 648 239 3,640 
2008–09 3,566 420 540 4,526 
Note: Data excludes cancer screening. 
Source: AIHW disease expenditure database. 
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Glossary 
5-year prevalence: The number of people alive at a specific date who were newly diagnosed 
with cancer in the previous five years. 
admitted patient: A patient who undergoes a hospital’s formal admission process to receive 
treatment or care. The treatment and care are provided over a period of time and can occur 
in hospital or in the person’s home (for hospital-in-the-home patients). 
Admitted Patient Costs Proportions: A measure used to calculate the cost-per-casemix 
adjusted separations. It is the ratio of admitted patient costs to total hospital costs, also 
known as the ’inpatient fraction’ (IFRAC). 
Anatomical Therapeutic Chemical Classification System code: Assigns therapeutic drugs 
to different groups according to the organ or system on which they act, as well as their 
therapeutic and chemical characteristics. 
benign: Non-cancerous tumours that can grow larger but do not spread to other parts of the 
body. 
Bettering the Evaluation and Care of Health (BEACH): An ongoing national survey of 
general practitioners in Australia. It is conducted by the Australian General Practice Statistics 
and Classification Centre at the University of Sydney. It involves a random sample of about 
1,000 general practitioners a year, each of whom records the details of 100 consecutive 
patient encounters. 
constant prices: Constant price expenditure adjusts current prices for the effects of inflation; 
that is, it aims to remove the effects of inflation.  
current prices: The term current prices refers to expenditures reported for a particular year, 
unadjusted for inflation. Changes in current price expenditures reflect changes in both price 
and volume. 
Diagnostic Related Groups: An admitted patient classification system that provides a 
clinically meaningful way of relating the number and type of patients treated in a hospital 
(that is, its casemix) to the resources required by the hospital. 
in situ: A Latin term meaning in place or position; undisturbed. 
Medicare Benefits Schedule (MBS): A Department of Health list that is part of the Medicare 
Benefits Scheme, the aim of which is to provide an entitlement to benefits for medical and 
hospital services for all Australian residents. 
metastasis: the process by which cancerous cells are transferred from one part of the body to 
another, for example, via the lymphatic system or the bloodstream.  
Pharmaceutical Benefits Scheme (PBS): The Australian Government–funded scheme that 
subsidises the cost of a wide range of pharmaceutical drugs and covers all Australians to 
help them afford standard medications. 
Repatriation Pharmaceutical Benefits Scheme (RPBS): This scheme provides assistance to 
eligible veterans (with recognised war, or service-related disabilities) and their dependants 
for both pharmaceuticals listed on the PBS and a supplementary repatriation list, at the same 
cost as patients entitled to the concessional payment under the PBS. 
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Health system expenditure on cancer and other neoplasms in Australia, 2008–09 
presents an overview of cancer expenditure focusing on the six cancers with 
the highest health system expenditure in each of four life stages 0–14, 15–24, 
25–64 and 65 years and over. 
Findings include:
•   Cancer and other neoplasms ranked sixth in terms of estimated health system 
expenditure on chronic diseases, accounting for 6.9% of total health system 
expenditure on all chronic diseases.
•   Expenditure on national population screening programs totalled $332 million.
•   From 2000–01 to 2008–09, total health system expenditure on cancer 
increased by 56% from $2,894 million to $4,526 million.
